Top news of the week: 08.09.2020.
Biotechnology, Neoplasm, Oncology, Johns Hopkins Hospital, Medical and health organizations, Hoechst AG
Startups
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program https://t.co/Vsl8VJSbQg https://t.co/e4j9yItIyy
OpenAfter Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
After being bounced by Bristol Myers after its Celgene takeover, Jounce is courting again, this time an early romance with Gilead.
RT @statnews: BREAKING: Experimental drug for ALS, dreamed up in a dorm room, offers patients glimmer of hope https://t.co/YuRRoZ4ZdK
OpenExperimental drug for ALS, dreamed up in a dorm room, offers patients glimmer of hope
Patients who took the medication retained a higher level of certain motor functions than those given a placebo, researchers say.
The covid vaccine will require billions of tiny glass vials — And this Italian billionaire family is making them
https://t.co/6T62h3rGkg By @giacomotognini https://t.co/1w4HKC1JhH
OpenThe Stevanato Group began 71 years ago by crafting specialty bottles for perfume and wine. Now they are perfectly positioned to profit from packaging pandemic cures.
Thousands of employees donned face masks to work around the clock in three daily shifts, seven days a week – making everything from insulin pen cartridges to miniature glass barrels and — ...
Check out some of the emerging companies in the gene and cell therapy spaces!
https://t.co/ZnmAYTJNQp
OpenSmall Biopharma Companies Emerging in Gene and Cell Therapy
Biospace recently analyzed key emerging cell and gene therapy companies to get a handle on how this evolving science is beginning to make its way from research into clinical applications.
That cash focuses on lemzoparlimab, I-Mab’s anti-CD47 monoclonal antibody, which AbbVie is also eyeing as a potential combination med with its blood cancer drug Venclexta. https://t.co/afwXhTFRxG
OpenAbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise
It’s a good day for Shanghai-based I-Mab, which has penned a $2 billion upfront-biobucks R&D deal with AbbVie while also nabbing $418 million from investors.
Fact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna.
Don’t assume things are true. https://t.co/VG09jhfRuH
OpenFact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna
Tens of thousands of users are sharing a series of claims that link Dr. Anthony Fauci, Bill Gates, George Soros and Jeffrey Epstein to Moderna, one of the leading contenders in the race to ...
New to #XconInsight: Learn what’s fueling San Francisco’s boom in AI, big data, and R&D by listening to our podcast and downloading our special report complementing Xconomy’s recent Xcelerating Life Sciences event.
https://t.co/bjU6lIz90L #XceleratingLS #XconSF
OpenNew Podcast and Special Report Explore How AI Is Revolutionizing Drug Discovery and Development
Learn what’s fueling San Francisco’s boom in AI, big data, and R&D, explore promising investment and partnership opportunities, and align the latest
Looking forward to participating in this panel w/ Andy Plump, Elias Zerhouni, Chris Viehbacher & Stelios Papadopolous (who apparently is a descendent of Alexander the Great :) Terrific conference overall and free this year via zoom https://t.co/JvsKwzxOdg
OpenPresident at USAIC
Top global BioPharma leaders to discuss Industry and Investment Outlook at USAIC’s 14th annual BioPharma Summit- Sept. 4, Virtual Event. Complimentary ...